Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZEAL

Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis

Zealand Pharma A/S logo

About Zealand Pharma A/S Stock (NASDAQ:ZEAL)

Advanced Chart

Key Stats

Today's Range
$17.59
$17.59
50-Day Range
$16.54
$19.20
52-Week Range
$9.93
$32.94
Volume
N/A
Average Volume
4,965 shs
Market Capitalization
$818.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Stock News Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

ZEAL Stock Analysis - Frequently Asked Questions

Zealand Pharma A/S (NASDAQ:ZEAL) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($6.31) by $1.70. The firm had revenue of $16.87 million for the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative net margin of 565.44% and a negative trailing twelve-month return on equity of 111.04%.

Zealand Pharma A/S (ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zealand Pharma A/S investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/10/2021
Today
7/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZEAL
CIK
1674988
Employees
355
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$161.99 million
Net Margins
-565.44%
Pretax Margin
-364.34%
Return on Equity
-111.04%
Return on Assets
-56.54%

Debt

Debt-to-Equity Ratio
0.93
Current Ratio
4.79
Quick Ratio
4.78

Sales & Book Value

Annual Sales
$46.54 million
Price / Sales
17.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
46,538,000
Free Float
45,514,000
Market Cap
$818.60 million
Optionable
Not Optionable
Beta
1.45
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ZEAL) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners